Stockscreener 앱 받기
2.39
0.84%
0.02
전일 마감가:
$2.37
열려 있는:
$2.35
하루 거래량:
2.08M
Relative Volume:
6.46
시가총액:
$107.86M
수익:
$1.49M
순이익/손실:
$-12.27M
주가수익비율:
-7.2075
EPS:
-0.3316
순현금흐름:
$-11.30M
1주 성능:
+43.11%
1개월 성능:
+129.81%
6개월 성능:
+180.85%
1년 성능:
+100.84%
1일 변동 폭
$2.28
$2.5396
1주일 범위
$1.65
$2.59
52주 변동 폭
$0.7006
$2.59
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
2.39 | 59.57M | 1.49M | -12.27M | -11.30M | -0.3316 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update - Kalkine Media
RenovoRx regains Nasdaq minimum bid price compliance - Investing.com
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo! Finance Canada
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment - Investing News Network
RenovoRx receives U.S. patent allowance for cancer device - Investing.com
RenovoRx receives U.S. patent allowance for cancer device By Investing.com - Investing.com Canada
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath, an Advanced Dual-Occlusion Catheter for Targeted Therapeutic Drug-Delivery for Cancer Treatment - marketscreener.com
RenovoRx Advances Targeted Localized Therapy for Advanced Pancreatic Cancer - geneonline.com
HC Wainwright Has Positive Outlook of RenovoRx Q3 Earnings - MarketBeat
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - sharewise.com
What is HC Wainwright's Forecast for RenovoRx Q3 Earnings? - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings: Narrower-than-Expected Loss Drives 11% Share RallyForward Guidance Trends - vinanet.vn
RNXT Q2 2026 Earnings: Narrower Loss Beats Estimate, Shares Jump 11%Share Dilution Risk - vinanet.vn
RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RenovoRx Q2 Earnings Call Highlights - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript - AOL.com
RenovoRx Q2 revenue surges 115% YoY to $909,000; raises FY26 guidance - scanx.trade
RenovoRx raises FY26 sales guidance to $3.75M-$4.25M vs $3.2M est - scanx.trade
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance By Investing.com - Investing.com Canada
RenovoRx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - Investing News Network
RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance - Investing.com
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BRIEF-RenovoRx Q2 Net Income USD -2.911 Million - TradingView
Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 - marketscreener.com
RenovoRx completes enrollment in phase III pancreatic cancer trial By Investing.com - Investing.com UK
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx completes enrollment in phase III pancreatic cancer trial - Investing.com
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer - TradingView
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead O - GuruFocus
RenovoRx pancreatic cancer trial closes enrollment; 78 deaths occurred - Stock Titan
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 - Yahoo Finance
RenovoRx Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) Climbs 3.12% to $1.16 as Oncology Pipeline Keeps Micro-Cap in FocusNarrow Range Breakout - dars.gov.et
RenovoRx reports RenovoCath’s first clinical use in sarcoma - Medical Device Network
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Inc (RNXT) Stock News Today - TradingKey
RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - marketscreener.com
RenovoRx Inc (RNXT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Earnings Preview: RenovoRx to Report Financial Results Post-market on August 12 - Moomoo
RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com - Investing.com Nigeria
RenovoRx’s RenovoCath used in sarcoma treatment for first time - Investing.com
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Renovorx Inc 주식 (RNXT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Jan 21 '26 |
Buy |
1.00 |
10,000 |
9,975 |
798,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 31 '25 |
Buy |
0.86 |
9,795 |
8,424 |
788,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
0.86%
0.31%
자본화:
|
볼륨(24시간):